RYTM RHYTHM PHARMACEUTICALS, INC.
FY2025 10-K
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Development and commercialization of MC4R agonist therapies to treat rare neuroendocrine diseases causing severe obesity and hyperphagia
- • New product focus: Anticipated 2026 US launch of IMCIVREE for acquired hypothalamic obesity, plus Phase 3 trial initiation for oral MC4R agonist bivamelagon
Management Discussion & Analysis
- • Revenue $422.5M to date from IMCIVREE product sales; commercial launch in US Q1 2021, France March 2022, ongoing growth expected
- • Net loss $196.5M in 2025 vs $260.6M in 2024; operating expenses increased with R&D down to $167.3M from $238M, SG&A up to $194.9M from $144.3M
Risk Factors
- • Regulatory risk from FDA, EC, MHRA approvals for setmelanotide expansion delays or denials impacting U.S., Canada, EU, UK launch
- • Geopolitical risk due to European operations and recent acquisition of Netherlands-based Xinvento B.V., with CHI program still in discovery phase
Financial SummaryXBRL
Revenue
$190M
Net Income
-$197M
Operating Margin
-101.2%
Net Margin
-103.6%
ROE
-141.3%
Total Assets
$480M
EPS (Diluted)
$-3.11
Operating Cash Flow
-$116M
Source: XBRL data from RHYTHM PHARMACEUTICALS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on RHYTHM PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.